JEOL Strengthens European Business in the Medical Equipment Segment

01-Oct-2020 Intellasia | BusinessWire | 7:30 AM Print This Post

TOKYO--(BUSINESS WIRE)--JEOL Ltd. (TOKYO:6951) (President & COO Izumi Oi) has opened a new facility in JEOL (EUROPE) B.V. (Zaventem, Belgium) on October 1, 2020, aiming to strengthen the Medical Equipment business in Europe.



This foundation, with three instruments in operation, not only offers customers the possibility of practical demonstrations and intensive service / application training, but also enables high-quality service and fast logistics from the dedicated warehouse.

This new approach is based on a long-term plan that whilst keeping pace with a high standard and matured medical environment in Europe, we will also cover emerging regions such as the Middle East, Eastern Europe and Russia, where the expected growth in economy and population can lead to a steady demand for medical infrastructure.

We will continue to promote overseas business intensively and hope that this new operation will be a milestone for more customer-oriented sales and service activities.

JEOL (EUROPE) B.V.: https://www.jeolbenelux.com/

Products (Clinical Chemistry Analyzer ):
https://www.jeol.co.jp/en/products/category_ca.html

JEOL Ltd.
3-1-2, Musashino, Akishima, Tokyo, 196-8558, Japan
Izumi Oi, President & COO
(Stock code: 6951, Tokyo Stock Exchange First Section)
www.jeol.com
https://www.jeol.co.jp/en/support/support_system/contact_products.html


Contacts

Hideyuki TANABE
E-mail: [email protected]
JEOL (GERMANY) GmbH
Gute Aenger 30, 85356 Freising, Germany
Corporate URL: https://www.jeol.de/

Contact Form: https://www.jeol.de/electronoptics-en/contact/
TEL: +49-8161-9845-0
FAX: +49-8161-9845-100

Taishi SAKAI
E-mail: [email protected]
JEOL (EUROPE) B.V.
Planet II, Gebouw B, Leuvensesteenweg 542, B-1930 Zaventem, Belgium
Corporate URL: https://www.jeolbenelux.com/

Contact Form: https://www.jeolbenelux.com/Contact-Us
TEL: +32-2-720-0560
FAX: +32-2-720-6134

 


Category: BusinessWire, PRAsia

Print This Post

Comments are closed.